---
title: "Structure Prediction Commoditizes: AlphaFold3 vs Boltz-2 vs Chai-1 Benchmarks"
source: "https://blog.booleanbiotech.com/alphafold3-boltz-chai1"
author:
  - "Boolean Biotech"
  - "Multiple benchmark papers 2025"
published: 2025-12-01
created: 2025-12-29
description: "Comprehensive comparison showing open-source Boltz and Chai match AlphaFold3 accuracy. Structure prediction becoming commodity - architecture no longer differentiating."
tags:
  - "clippings"
---

## The Commoditization

**Key Finding:**
All three models (AlphaFold3, Boltz, Chai-1) are AF3-derivatives trained on same data. Performance is generally very similar.

**Why AlphaFold3 Gets Little Attention:**
Despite being excellent, parameters not available. DeepMind moved to walled environment precluding commercial use.

## Benchmark Comparisons

**CASP15 Results:**
- Chai-1: 0.849 average LDDT (monomer predictions)
- ESM3: 0.801 average LDDT
- Boltz-1: Matches AlphaFold3 and Chai-1 on many benchmarks

**PoseBusters (Ligand Docking):**
- Chai-1: ~77% success
- AlphaFold3: 76% success

**Boltz-2 Evaluation (2024-2025 unseen complexes):**
- Matches or moderately improves over Boltz-1
- Competitive with Chai-1
- Lags slightly behind AlphaFold3, especially on antibody-antigen

## Where AlphaFold3 Still Wins

**Antibody-Antigen Complexes:**
AlphaFold3 outperforms Boltz-1 and Chai-1, especially on generalization to unseen antigens. This is one area where proprietary advantage remains.

## The Open-Source Winners

**Boltz Advantages:**
- Training code AND neural network architecture included
- Hackable, clean codebase
- Most open model of the three
- Boltz-2 adds binding affinity prediction (unique capability)

**Chai-1 Advantages:**
- Inference code with pre-compiled models
- Protein language model embeddings
- Easy deployment

## Relevance to JEPA Thesis

**Critical implication for the thesis:**

1. **Structure prediction is commoditized** - open-source matches proprietary
2. **Architecture alone doesn't differentiate** - all use same AF3 architecture
3. **Where's the moat?** Not in static structure prediction

**This SUPPORTS the JEPA thesis:**
If structure prediction commoditizes, the value shifts to:
- **Trajectory prediction** (how does structure change over time?)
- **Clinical outcome prediction** (what does this structure mean for patient?)
- **Action-conditioned prediction** (what happens if we intervene?)

World models address these questions. AlphaFold-style models don't.
